Ion Beam Applications (IOBCF) Stock Price, News & Analysis

Company Overview

Ion Beam Applications (OTCMKTS: IOBCF), headquartered in Louvain-la-Neuve, Belgium, is a global developer and provider of particle accelerator technology for cancer treatment and medical imaging. Founded in 1986 as a spin-off from the Catholic University of Louvain, the company has built its reputation on the design, manufacture and installation of cyclotron-based systems. Its core expertise lies in proton therapy solutions, which use high-energy proton beams to target tumors with precision, minimizing damage to surrounding healthy tissue.

The company’s flagship products include the Proteus® ONE and ProteusPLUS® proton therapy platforms. These systems integrate advanced beam delivery, imaging and treatment planning tools to support a range of clinical applications, from pediatric oncology to complex head and neck cancers. In addition to proton therapy, Ion Beam Applications offers cyclotron solutions for the production of radioisotopes used in positron emission tomography (PET) imaging. The Cyclone® line of compact cyclotrons enables hospitals and imaging centers to produce short-lived isotopes on site, improving patient access to diagnostic scans.

Beyond equipment sales, Ion Beam Applications provides comprehensive services throughout the project lifecycle. Its global network spans Europe, North America, Asia Pacific and the Middle East, delivering site assessment, turnkey installation, commissioning and ongoing maintenance. The company also offers training programs for clinical and technical teams, along with quality assurance tools and software to ensure high standards of safety and performance at treatment centers worldwide.

Under the leadership of Chief Executive Officer Vincent Mannaerts and a management team seasoned in medical technology and life sciences, Ion Beam Applications continues to pursue innovation in particle therapy and radiopharmaceutical production. The company collaborates with academic institutions, cancer centers and healthcare providers to advance research, expand clinical applications and improve patient outcomes. Through its integrated approach to proton therapy and PET diagnostics, Ion Beam Applications remains at the forefront of precision oncology solutions.

Key Stats

• Today's Range: $13.36 to $13.36
• 50-Day Range: $11.15 to $14.23
• 52-Week Range: $10.15 to $15.75
• Volume: 450 shs
• Average Volume: 755 shs
• Market Capitalization: N/A
• P/E Ratio: 157.61
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IOBCF Stock Analysis - Frequently Asked Questions

How have IOBCF shares performed this year?

Ion Beam Applications' stock was trading at $13.85 at the beginning of 2025. Since then, IOBCF shares have decreased by 3.5% and is now trading at $13.36.

How do I buy shares of Ion Beam Applications?

Shares of IOBCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/17/2025
• Next Earnings (Estimated): 8/28/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:IOBCF
• CIK: N/A
• Web: www.iba-worldwide.com
• Phone: (321) 047-5811
• Fax: N/A
• Employees: 2,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 153.84
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A